Expansion of Quotient Sciences’ Alnwick, UK manufacturing facility complete

The major expansion of Quotient Sciences’ drug substance manufacturing facility in Alnwick has been completed, promising increased manufacturing systems and capabilities. 

The expansion will increase Quotient Sciences’ multipurpose capacity of up to 15 GMP reactor streams with volumes ranging from 5–150 L. Batch and continuous flow chemistry technologies can be deployed for the optimisation of drug substance manufacturing processes. The facility has also been designed adopting Industry 4.0 principles, which include a predictive process control system to improve the transfer of small-scale process research and development to commercial-scale manufacturing for clinical use. Quotient Sciences’, a CDMO and CRO, provides integrated and tailored programs throughout the drug development and manufacturing pipeline. With a workforce of 200 strong across disciplines ranging from process chemistry, solid-state characterisation, radiosynthesis, bioanalysis, and formulation development, the company was presented with the award for ‘Most Inspirational North East (UK) Science Employer’ from STEM Learning. 

Mark Egerton, CEO of Quotient Sciences, stated: “Since acquiring the Alnwick facility in 2021, our objective has been to incorporate drug substance services into our integrated Translational Pharmaceutics platform combining drug product manufacturing and clinical testing. By working with customers at the point of candidate nomination, we can now design the most streamlined programs and significantly accelerate their development timelines.” 

Source: Quotient Sciences Completes Major Expansion of Drug Substance Manufacturing Facility